Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics, Inc. (PTCT) Form 144 filing: An insider has notified intent to sell up to 10,739 common shares through Fidelity Brokerage around 05 Aug 2025. Based on the stated aggregate market value of $555,662.71, the proposed sale is priced near $51.75 per share. The shares were obtained via restricted-stock vesting on 01 Aug 2025 and will be sold on Nasdaq.
The block represents roughly 0.014 % of PTCT’s 79.26 million shares outstanding, implying negligible dilution or liquidity impact. While the monetary size is modest for a company of PTCT’s scale, the filing indicates near-term insider profit-taking shortly after vesting, a datapoint some investors watch as a sentiment signal.
PTC Therapeutics, Inc. (PTCT) filed a Form 144 signaling an affiliate’s intent to sell up to 2,516 common shares through Fidelity Brokerage Services on or about 15 July 2025. The shares were recently acquired via restricted-stock vesting on 14 July 2025 and have an aggregate market value of approximately $124,435, implying a reference price near $49.45 per share. With 79.26 million shares outstanding, the planned disposition represents less than 0.01 % of total equity—too small to affect liquidity, control, or valuation. No additional sales by this insider have occurred within the past three months, and the filing provides no further operational or financial commentary.